Mesenchymal stem cell exosomes inhibit nucleus pulposus cell apoptosis via the miR-125b-5p/TRAF6/NF-κB pathway axis

Yang Duan1, Cheng Yu1, Wenhao Kuang1

  • 1Department of Spinal Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510260, China.

PubMed

Insights

Mesenchymal stem cell-derived exosomes deliver miR-125b-5p to inhibit nucleus pulposus cell apoptosis and reduce intervertebral disc degeneration. This study elucidates a key mechanism for treating lower back pain caused by disc degeneration.

Area of Science:

  • Biomedical Engineering
  • Cell Biology
  • Molecular Biology

Background:

  • Intervertebral disc degeneration (IVDD) is a major cause of lower back pain, and its underlying mechanisms require further elucidation.
  • Mesenchymal stem cell (MSC) transplantation shows therapeutic potential for IVDD, but the specific molecular pathways are not fully understood.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) delivered by MSC-derived exosomes in the treatment of IVDD.
  • To elucidate the molecular mechanism by which MSC-exosomes attenuate nucleus pulposus cell (NPC) degeneration.

Main Methods:

  • Bioinformatic screening and high-throughput sequencing identified candidate miRNAs.
  • MSC-exosomes were characterized using TEM, NTA, and Western blot.
  • Cell viability, apoptosis, miRNA expression, and protein levels were assessed using CCK-8, flow cytometry, TUNEL, RT-qPCR, and Western blot assays.
  • A dual-luciferase reporter assay and *in vivo* rat models were used for mechanism validation.

Main Results:

  • miR-125b-5p expression was significantly lower in degenerated disc tissues but high in MSC-exosomes.
  • MSC-exosomes effectively delivered miR-125b-5p into NPCs, inhibiting apoptosis and promoting cell viability.
  • miR-125b-5p targeted TRAF6, downregulating its expression and subsequently inhibiting NF-κB activation.

Conclusions:

  • MSC-exosomes attenuate IVDD by delivering miR-125b-5p, which targets TRAF6 and inhibits the NF-κB pathway.
  • This finding provides a novel therapeutic strategy for IVDD by leveraging the exosomal delivery of specific miRNAs.